<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01283425</url>
  </required_header>
  <id_info>
    <org_study_id>G080106/B</org_study_id>
    <nct_id>NCT01283425</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions</brief_title>
  <acronym>Daily Life</acronym>
  <official_title>An Open-label, Randomized, Two-period Crossover Study to Evaluate the Safety Use of the InsuPatch Device in Daily Life Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insuline Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insuline Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an open-label, randomized, two-period crossover study. Up to one hundred and&#xD;
      twenty (120) subjects with type 1 diabetes mellitus (T1DM) who use the MiniMed paradigm&#xD;
      insulin pump, who meet the inclusion/exclusion criteria and who provide written Informed&#xD;
      Consent will be enrolled in the study. The aim of the study is to examine the safety of the&#xD;
      InsuPatch device in a home use setting. Mild Hypoglycemia,hyperglycemia and Adverse events&#xD;
      will be compared between two phases of the study : 3 months with the use of the device and 3&#xD;
      months without the use of the device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to show that safety parameters are similar, when&#xD;
      delivering insulin subcutaneously in subjects with type I diabetes using the InsuPatch device&#xD;
      along with the Medtronic Minimed Paradigm insulin infusion pump and the Medtronic Minimed&#xD;
      Quick-SetÂ® infusion set compared to subcutaneous insulin delivered with the above mentioned&#xD;
      equipment, without the InsuPatch device.&#xD;
&#xD;
      The participation of each subject in this study will be up to seven months and will include&#xD;
      three phases: one week Run in phase , 3 months with device use and 3 months without device&#xD;
      use. Study will include 4 clinic visits and bi weekly calls. During the entire study the&#xD;
      subjects will be requested to preform at least 5 blood glucose self measurements and record&#xD;
      results in a logbook.At each visit blood will be drawn for HBA1C test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of mild hypoglycemia events (Blood Glucose&lt;60mg/dl) with InsuPatch and without.</measure>
    <time_frame>safety will be assesed after 6 months at the study completion</time_frame>
    <description>The confirmatory safety endpoint is, for each subject, frequency of mild hypoglycemia events (Blood Glucose&lt;60mg/dl) with InsuPatch and without.&#xD;
The number of events will be assessed from subject logbook and will be compared between two arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of hyperglycemic events (BG&gt;300 mg/dl, Fasting BG&gt;250 mg/dl) with InsuPatch and without.</measure>
    <time_frame>safety will be assesed after 6 months at the study completion</time_frame>
    <description>Frequency of hyperglycemic events (BG&gt;300 mg/dl, Fasting BG&gt;250 mg/dl) with InsuPatch and without.The number of events will be assesed from subject logbook and will be compared between two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE's) count with InsuPatch and without.</measure>
    <time_frame>safety will be assesed after 6 months at the study completion</time_frame>
    <description>Adverse events (AE's) whether or not deemed related to study device with InsuPatch and without.The number of events will be assesed dering the subject visits and bi-weekly calls and will be compared between two arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InsuPatch use for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InsuPatch</intervention_name>
    <description>Heaters for single use and a permanent control unit.</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject's age range 18- 65 years old (including 18 and 65 years old)&#xD;
&#xD;
          2. BMI: 18-35 kg/m2&#xD;
&#xD;
          3. Type 1 diabetes patients using a MiniMed Paradigm insulin pump for at least six&#xD;
             months, who are administering insulin Lispro or Insulin Aspart and are using the&#xD;
             Quick-set infusion set.&#xD;
&#xD;
          4. Patients with T1DM whose HbA1c values are at or below 9.5% (including 9.5%) and at or&#xD;
             above 6% (including 6%).&#xD;
&#xD;
          5. Agree to sign consent form before any study-specific tests or procedures are to be&#xD;
             performed.&#xD;
&#xD;
          6. Subject's completed at least 14 measurements during the Run-In Phase and readiness to&#xD;
             continue the study with at least 5 blood glucose recordings per day and keep a logbook&#xD;
             during the study period.&#xD;
&#xD;
          7. Subject readiness to use the InsuPatch, his comprehension of the study requirements&#xD;
             and treatment procedures.&#xD;
&#xD;
          8. Willingness to comply with all specified follow-up evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Breast feeding women.&#xD;
&#xD;
          3. Alcohol addiction&#xD;
&#xD;
          4. CABG (Coronary Artery Bypass Graft), MI (Myocardial Infarction) or active Ischemic&#xD;
             Heart Disease prior to study date.&#xD;
&#xD;
          5. CVA (cardiovascular accident) or TIA (transient ischemic accident) events prior to&#xD;
             study date.&#xD;
&#xD;
          6. Uncontrolled hypertension (blood pressure in mm HG &gt;160 systolic or &gt; 95 diastolic) .&#xD;
&#xD;
          7. Any history of gastroparesis or enteroparesis.&#xD;
&#xD;
          8. Abnormal kidney and/ or liver function tests. (Defined as Creatinine &gt;1.5 mg/dL, liver&#xD;
             tests&gt; 2 times the upper limit of normal).&#xD;
&#xD;
          9. A severe hypoglycemic event requiring a glucagon injection or intravenous glucose&#xD;
             infusion within the last six months prior to study inclusion.&#xD;
&#xD;
         10. Hypoglycemia unawareness.&#xD;
&#xD;
         11. Diabetic ketoacidosis (severe, with hospitalization) within the last six months prior&#xD;
             to study inclusion.&#xD;
&#xD;
         12. Psychological incompetence.&#xD;
&#xD;
         13. Signs of drug abuse.&#xD;
&#xD;
         14. Any other clinical condition or history, which seems to be relevant for the Principle&#xD;
             Investigator to disqualify a participant.&#xD;
&#xD;
         15. Subjects with diminished skin integrity, Excessive fibrosis, lipo-hypertrophy or&#xD;
             eczema at infusion sites.&#xD;
&#xD;
         16. Heat sensitive subjects.&#xD;
&#xD;
         17. Subjects involved in or planning to participate in other studies.&#xD;
&#xD;
         18. Subjects using any drug therapy, other than insulin, to control their blood glucose&#xD;
             levels.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wainstein Julio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolfsom Medical Center, Holon, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Itamar Raz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klonoff David, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mills Peninsula Health Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naim Shhada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Orit Hamiel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moshe Philips, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schnieder Children's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anat Yaffe, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hiullel Yaffe Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mills-Peninsula Health Services</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haddasah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's hospital</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.insuline-medical.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2011</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MiniMed Paradigm insulin pump</keyword>
  <keyword>insulin Lispro</keyword>
  <keyword>Insulin Aspart</keyword>
  <keyword>Quick-set infusion set</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

